#Guficbiosciences Niche Small cap Pharma Company ?

Detailed Thread 🧵🧵

CMP - ₹ 215

Like & Retweet for better reach ! Image
1. Company Overview

Gufic is an R&D focused pharma company that is involved in contract manufacturing, branded generics, herbal formulations and new drug delivery systems.

The company entered into the contract manufacturing business in 2007 and today it manufactures
lyophilized injectables for most of the large pharma companies in India.

Company then entered the branded generics business with the launch of several products in the critical care space.
Today, they are present in branded generic drugs across infertility, pediatric, herbal, dermatology, bone health and pain management therapies as well.
2. Revenue Split

Gufic’s pharma business is divided into 4 broad segments - their domestic business which consists of branded generics, their CMO business where they manufacture lyophilized injectables to large pharma companies, Image
their International business which consists of exports and their API business.

The domestic business is their largest business which contributes to about 50% of their overall revenues.

The CMO business is the second largest contributing approximately 30-35% of revenues.
The International business contributes to about 15-20% of revenues whereas API is the smallest segment which contributes to about 5-7% of revenues
3. Domestic Business:

The domestic business consists of 6 divisions divided into 3 categories - Gufic Super Speciality, Gufic Mass Specialty and Gufic Specialty. Image
Their domestic branded business is their best business and has the highest margins. They have a combined field force of over 1100 who cater to over 1 lakh 20 thousand doctors all over India. Let us look at each of the divisions
Criticare:
In the Criticare division the company has products in Antibacterial, Antifungal, Gastrointestinal, Pain and Blood products. The products in this division are used for critically ill patients like patients suffering from life
threatening conditions who are kept in the ICU. This is Gufic’s largest division and contributes to more than half of its domestic revenues. Gufic’s USP in this division is that most of the drugs that are used in critical care treatment are from MNC pharma companies,
so they end up being very expensive. Gufic provides a cost effective alternative to hospitals by providing the same quality drugs at a fraction of the price.
Ferticare: his division consists of drugs used for the treatment of infertility. The major product categories are Hormones, Recombinant Products, Infertility Supplements. Their key products in this segment are Puregraf, Cetrofirst, Puretrig and Gufigest
which are hormones used in the treatment of infertility.

Healthcare: Under Gufic Healthcare, they market and sell various Herbal Products and Nutraceuticals which are extracted from natural products. These products are mainly used for Bone Health, Pain Management, Immunity,
Gastro, Stress and Wound care. Their flagship brand in this division is known as Sallaki which is a product made from a plant known as Boswellia Serrata. Boswellia Serrata has historically been used in Indian Ayurveda to treat ailments like
arthritis, ulcerative colitis, coughs, sores and asthma.

Spark: Gufic Spark caters to the Anti Infective, Gastro, Gynaec, Pediatric, Respiratory and Nutraceutical areas. They have a field force of over 180 in this division and market the drugs to General Practitioners,
Physicians, Gynecologists and Pediatricians. The flagship brand in this segment is Stretch-Nil - which is a product used to reduce stretch marks during pregnancy.
Aesthaderm: Gufic Aesthaderm is primarily focused in Aesthetic Dermatology. The product categories they are involved in are Neurotoxins, Anti Aging, Hyperpigmentation, Sunscreens, etc. They have a field force of over 40 in this segment.
They are the first Indian company to launch a Botulinum toxin product in India under the brand name Stunnox. Apart from Botulinum toxin, they have a range of other skin care products that complement Stunnox in the Aesthaderm division.
Stellar: The products in this division are used in Bone Health, Pain Management, Fractures, Arthritis, Pregnancy, Post Menopausal segments. The division has a field force of over 60 and is primarily focused on orthopedic and gynecology products.
This division is Gufic’s entry into the sub-chronic therapies which are generally higher value and higher margin products.
Botulinum Toxin

Botulinum toxin is a neurotoxin which is one of the most poisonous substances on earth. It is produced by a bacteria called Clostridium botulinum and one teaspoon of the substance can kill the entire human population. Image
It causes muscle paralysis by blocking the connection of the muscles to the nerves that are responsible for the contraction of these muscles. However, when used in very very small doses, it can be used to treat various conditions.
Gufic has launched their brand of Botulinum Toxin in partnership with Prime Bio. Their product is priced at a lower price point than Botox and management says that the quality is comparable. In their agreement with Prime Bio, Gufic has purchased the cell line outright and
has full ownership of the cell line. They produce the toxin at their Navsari facility and also have a profit sharing agreement with Prime bio. The market for botulinum toxin is very small in India currently with management indicated it is anywhere between 60 to 120 crores.
Dual Chamber Bags

Gufic collaborated with Technoflex - a European company which is a leader in IV drugs to launch Dual Chamber Bags. Dual Chamber bags are basically polypropylene bags that have a seal which separates the powdered drug and its diluent. Image
By just squeezing the bag, it will break the seal separating the drug and diluent which can then be administered to the patient. The drug is packaged in the exact dosing quantity which eliminates reconstitution error, the bag is sealed which prevents
contamination and it saves a lot of time for medical professionals. Previously, Dual Chamber bags had to be imported which made them very expensive to use. Gufic is producing them in a cost effective way to make it affordable to the Indian public.
These products will be marketed under their Criticare division and they are looking to take a significant chunk of the lyophilized antibiotic and antifungal drug market.
CMO business:

Gufic is one of the largest contract manufacturers for lyophilized injectables. Their clients in this segment are the largest pharma companies in India like Abbott, Sun Pharma, Cipla, Dr Reddy’s and many others. Image
Gufic main strength is their capabilities in lyophilization and they provide over 170 lyophilized products to over 70 companies in India. They are one of the largest suppliers of Doxycycline, Tigecycline, Gonadotropins, Liposomal Amphotericin B,
Micafungin to Indian companies in the branded generic space.

International business: The business consists mostly of branded generics which are marketed in Emerging markets and in some Developed markets. Image
Currently, Asia and Europe are their biggest markets. Gufic has over 130 products in over 15 countries. They have over 150 in the pipeline that will be registered in over 30 countries.
The management has said that they are looking to increase the share of this business in the future. This is also evidenced in the increasing share of the export revenues. The increase in 2022 domestic revenue is due to the one off increase in Remidesivir sales due to Covid.
API business:
In the API business, they mainly manufacture Antifungals, Antibacterials, Anesthetics and intermediates for Antifungals. So the company is fully integrated for manufacturing antifungals. They have a dedicated facility to manufacture APIs at their Navsari Plant. Image
API is currently their smallest division but it is strategically a very important division for them. Gufic is majorly a formulation manufacturer and are dependent on imports to meet their API needs.
The API business provides them with backward integration for their APIs and reduces their dependence on imports for their key products. Currently, about 50% of the APIs produced are used for captive consumption and the remaining 50% are sold.
Capex:
They are putting up a Greenfield capacity in Indore. It will be a facility for Lyophilized and Liquid injectables which can cater to the markets of US and EU. They will be installing a capacity to manufacture 36 million lyophilized vials, 15 million pre-filled syringes
and 60 million million units of liquid injectables. Currently, the company has a capacity of 48 million lyophilized vials. This capex will increase their capacity by 75% and they will have the largest lyophilization capacity in India Image
and with the enormous increase in pre-filled syringe and liquid injectables capacity, this capex will increase their capacity by almost 1.5 times. They also have a big land bank in Indore which will be used for future expansions.
The civil work on the facility is done and it is expected to commercialize in Q1 FY24. The company has also installed a Penem block at their Navsari Facility. This block was supposed to be included in Indore but the company decided to shift it to Navsari
because they would be able to bring it online faster and it would save them on costs as the Navsari facility already has the basic infrastructure. This block has a capacity of 3 million lyophilized vials, 24 dual chamber bags and 30 million vials of dry powder injections.
The facility will begin production in Q3 FY23

Risks:

They are not fully backward integrated which means that they are exposed to the volatility in API prices. They are still largely a formulations company who depend on API imports to manufacture their formulations
which is a risk to the business.

Competition is also a big risk in the Pharma business and we have been seeing more and more pharma companies entering into the sterile and lyophilization space lately. And lastly, the company faces regulatory risk -
especially if they are entering into regulated markets whose stringent requirements can significantly increase manufacturing costs significantly
Watch the detailed video on #Guficbio



Like and Retweet for better reach !!

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Value Educator

Value Educator Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @ValueEducator

Dec 5
#Indoco Remedies’ management seems to be very optimistic about strong expansion in margins. They have an export order book of ₹150 with export margins expected to increase by 400-500 bps over the next 3 quarters. Image
They will achieve EBITDA margins over 20% in this financial year and have said that they are confident of taking margins to over 25% over the next 3 years. Image
Management has said that there is huge scope for operating leverage to play out at the Baddi facility. They expect to reach 70% capacity utilization by December 2023 Image
Read 6 tweets
Dec 2
#Moldtekpackeging

Small Cap Consistent Compounder ?

Detailed Thread 🧵🧵

Like & Retweet for Better reach !

CMP - ₹ 900 Image
1. Company Overview
Mold-tek packaging is established in 1985 and it is one of the leading player in the rigid packaging industry in India

Mold-tek was the first company in India to launch
In Mould Labelling (IML) technology in FY 2011
Mold-tek make their own molds, labels and robots

The company has blue chip clientele such as Asian Paints, Akzo Nobel, Kansai Nerolac, Castrol, Shell, BPCL, Cadbury, Amul and HUL
Read 30 tweets
Nov 16
Detailed 🧵 on #SakarHealthcare - Micro Cap which is doing Huge Capex for Oncology Drugs 💊💊

Like & Retweet for better reach !

CMP - ₹ 233
Company Overview:

Sakar Healthcare is a pharmaceutical company incorporated in 2004. They do contract manufacturing majorly for sterile drugs and they also export to various emerging markets under their own brands.
They manufacture a variety of dosage forms including Liquid Injections, Lyophilized Injections, Dry Powder Injections, Dry Powder Syrups and Oral Solids Like Tablets and Capsules. Their biggest therapy area is Antibiotics which contributes to 41% of revenues,
Read 20 tweets
Nov 10
#SuvenPharma Q2 23 Concall Highlights

Like & Retweet for better reach !

1. De-growth in CRAMS and growth in specialty chemicals division.

2. Having better visibility now. Getting understanding from innovators that next year will be a normal year
3. 3. Suven pharma business should be looked at Year on Year and not qtr to qtr due to change in product mix and CRAMS orders can have Qtr to Qtr Volatility

4. For complete year EBITDA margins guidance of 40% + is intact
5. This qtr revenues from pharma was lower compared to agro chemicals but it will normalize over the next qtrs.

6. In this qtr Very small revenue from the covid drug. From next qtr it should come. It will be one off order
Read 9 tweets
Nov 8
#RACLGeartech Business Model 🧵🧵

CMP - ₹ 613

Like & Retweet for better reach ! Image
1. About Company
Raunaq Automotive Components Limited(RACL) was incorporated in 1983 and is engaged in manufacturing transmission gears and shafts for automotive and industrial applications.
It had a solid vision to create a diverse customer base ranging from two-wheelers to Heavy Commercial vehicles, a 100 CC commuter bike to a 1200 CC Sports Motorcycle, a 150 cc Premium Scooter to a 1500 CC bike.
Read 21 tweets
Nov 4
Net Profit vs Cash Flow from operations (CFO) - What is more important?

A short thread with examples

Like & Retweet for better reach !
1. Net income is the profit a company has earned for a period, while cash flow from operations measures the cash going in and out during a company's day-to-day operations i.e., the cash which is generated through its core business.
2. Net income is calculated by subtracting the cost of goods sold, operating expenses, depreciation & amortization, interest expense and taxes from total revenue.
Read 15 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(